StockNews.com Begins Coverage on Affimed (NASDAQ:AFMD)
StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research report released on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other equities analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on […]
StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research report released on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other equities analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on […]
